



**The Clatterbridge
Cancer Centre**
NHS Foundation Trust

Clatterbridge Road
Bebington
Wirral
CH63 4JY

Tel: 0151 556 5000
Web: www.clatterbridgecc.nhs.uk

Date: 4 May 2020

Re: Freedom of Information Request
Ref: 94- 2020

Thank you for your email dated the 15th April 2020, requesting information regarding patient treatment figures.

The information that you require is as follows:

Within your health trust how many patients are currently (within the past 3 months) being treated with the following regardless of patient diagnosis:

N.B - Figures include patients who received at least 1 cycle of the named drug between 22nd January 2020 and 21st April 2020 (3 months)

Please note in accordance with the Data Protection Act 2018 our Trust is unable to release all of the information requested. The Clatterbridge Cancer Centre NHS Foundation Trust (CCC) is a relatively small Trust and by providing this level of detail where the number of patients is less than or equal to five increases any 'potential' risk of this data becoming identifiable information and thereby contravening one or more of the Data Protection Principles by releasing it into the public domain. Confidentiality is expected in such matters. This information is therefore exempt under Section 40: Personal Information, of the Freedom of Information Act 2000. The areas where this exemption has been applied are shown below:

Abemaciclib + aromatase inhibitor = 9 patients

Abemaciclib + Fulvestrant = 27 patients

Alpelisib + Fulvestrant = 0 patients

Atezolizumab = 74 patients (some in combination with other drugs)

Avelumab = 16 patients (some in combination with Axitinib)

Bevacizumab = 34 patients (some in combination with other drugs)

Eribulin = 16 patients

Everolimus + Exemestane = 0 patients

Fulvestrant as a single agent = 35 patients

Gemcitabine + paclitaxel = 15 patients

Herceptin IV = 0 patients (single agent), exempt under S.40 (patients in combination)

Herceptin SC = 0 patients

Lapatinib = 0 patients

Neratinib = 23 patients

Nivolumab = 140 patients (includes some in combination)

Olaparib = 23 patients (includes some in combination)

Palbociclib + aromatase inhibitor = 17 patients

Pembrolizumab = 301 patients (includes some in combination)

Pertuzumab + trastuzumab + docetaxel = 31 patients

Ribociclib + aromatase inhibitor = exempt under S.40

Ribociclib + Fulvestrant = exempt under S.40

Talazoparib = 0 patients

Transtuzumab biosimilar IV = 188 patients (includes some in combination)

Transtuzumab biosimilar SC = 182 patients (includes some in combination)

Trastuzumab emtansine = 24 patients

Should you require any further information please do not hesitate to contact me on the email address provided below.

Please remember to quote the reference number above in any future communications.

If you are dissatisfied with the handling of your request, you have the right to ask for this to be investigated internally.

If you are dissatisfied with the information you have received, you have the right to ask for an internal review.

Both processes will be handled in accordance with our Trust's Freedom of Information Policy and the Freedom of Information Act 2000.

Internal investigation and internal review requests should be submitted within two months of the date of receipt of the response to your original letter and should be addressed to: Freedom of Information Review, The Clatterbridge Cancer Centre NHS Foundation Trust, Clatterbridge Road, Bebington, Wirral, CH63 4JY

If you are not satisfied with the outcome of the internal investigation/review, you have the right to apply directly to the Information Commissioner for a decision. The Information Commissioner can be contacted at: Information Commissioner's Office, Wycliffe House, Water Lane, Wilmslow, Cheshire, SK9 5AF.

In order for us to ensure customer satisfaction and to monitor compliance with the Freedom of Information Act 2000, we would be grateful if you could take a couple of minutes to complete a short feedback form via the link below:

<https://www.surveymonkey.co.uk/r/H39RFMM>